On 3 June 2026 the regulator alleged the past five years of revenue do not exist.

• The allegation. SEBI interim ex-parte order alleges ₹15.15 lakh crore of consolidated revenue across FY21–FY25 — described as ~99.8% of subsidiary-attributed turnover — was misstated, and that ₹926 cr of promoter-linked flows went undisclosed as related-party transactions.
• The auditor problem. Forensic auditor BDO reported denied ERP access; statutory auditor BSD & Co. (a small Bengaluru firm) failed to submit promised working papers to SEBI. Matter referred to NFRA per the order.
• The reply window. Promoter-Chairman Rajesh Mehta barred from securities markets for three years (interim). Company's 30-day reply window closes ~3 July 2026 — the first formal substantive disclosure window since the Feb-2019 investor presentation.

~98-99% of revenue lives in a Singapore subsidiary the listed-parent auditor does not directly test.

• The offshore book. REL Singapore Pte Ltd booked ₹4,16,072 cr of FY25 turnover per the FY25 AR Annexure III — 98.3% of FY25 consolidated revenue (₹4,23,099 cr). The Indian listed parent reports zero foreign-exchange earnings or outgo in both FY24 and FY25.
• The Indian shell. Standalone parent FY25: ₹7,027 cr revenue, ₹29 cr PBT, 112 permanent employees per the FY25 AR. The named 'Rajesh Exports' jewellery-export business at the listed entity is effectively dormant (nil forex earnings).
• The missing bridge. Valcambi SA standalone CY23 revenue ~₹543 cr versus GGR (Valcambi parent) consolidated ~₹2.92 lakh cr — no audited reconciliation between Valcambi standalone and group consolidated revenue has been published since the 2015 acquisition.

₹7.79 lakh crore of FY26 revenue produces 2% ROCE and ~0.014% operating margin.

Reported revenue scales with bullion throughput and gold price, not with value added — a refiner-trader earns roughly 20-50 cents per ounce on inventory that takes title for hours. The decisive number is below the P&L: FY21-FY25 cumulative operating cash flow is negative ~₹1,921 cr against ~₹4,434 cr of cumulative operating profit. A business that does not convert profit to cash through a full cycle does not compound — it consumes the capital that funds it.

Cash drained, dividends stopped, communication stopped, and the Investments line ballooned.

• Standalone cash drained. Standalone cash & bank balances were ₹2,053 cr at FY21 and ₹1,891 cr at FY25 per AR MDAs — well below the multi-thousand-crore reserves implied by earlier balance sheets. No dividend, buyback, capex, or acquisition disclosed in any MD&A explains the longer-run drawdown.
• Investments line ballooned ~9× in two years. Consolidated Investments grew from ₹1,292 cr (FY24) to ₹11,797 cr (FY26) — now ~4× market cap — alongside Other Liabilities expanding ~₹16,438 cr (₹6,170 cr FY24 → ₹22,608 cr FY26).
• Communication blackout. Last investor presentation Feb 2019; last available earnings-call transcript Q2 FY2018. Dividend zero in FY23–FY26 against a written 'consistent payout' policy. Asha Mehta — Audit Committee chair, same Mehta surname as the Executive Chairman — reappointed Independent Director for five more years from 30-Jun-2025 at the 30-Dec-2025 AGM.

Valcambi is real. The path from Valcambi to the listed shareholder is not.

The asset. Valcambi SA — acquired 2015 for ~US$400M per company disclosure — is one of three top global LBMA Good Delivery refiners with ~2,000 t/yr capacity. Accreditation, customer book, and Swiss-cluster cost base are decade-plus to replicate. A bull SOTP anchoring on the 2015 deal value plus standalone cash sits well above the current market cap, but the implied INR equivalent depends sharply on FX and assumed Valcambi book value.

The holdco. That asset sits inside REL Singapore, which sits inside the listed entity, audited by the small Bengaluru firm whose working papers SEBI says were not produced. The ₹11,797 cr Investments line the bull case anchors on is itself the line SEBI alleges is unsupported.

The workout. A 5-to-10-year thesis here is not a compounder bet — it is a structural workout. Translating Valcambi-as-asset into listed-shareholder value requires segment carve-out, partial Valcambi listing, or strategic sale. No such pathway has been announced since the 2015 acquisition.